Affinage

JAK1

Tyrosine-protein kinase JAK1 · UniProt P23458

Length
1154 aa
Mass
133.3 kDa
Annotated
2026-06-10
100 papers in source corpus 35 papers cited in narrative 35 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JAK1 is a non-receptor tyrosine kinase that serves as an obligate signaling hub for cytokine and interferon receptors, coupling receptor engagement to STAT activation across immune, hematopoietic, and developmental programs (PMID:8232552, PMID:28965767). It is mutually dependent on partner kinases for interferon signaling — acting with TYK2 in the IFN-α/β pathway and with JAK2 in the IFN-γ pathway — where its activity and pseudokinase (JH2) domain are required for correct receptor complex assembly and STAT phosphorylation (PMID:8232552, PMID:9249040, PMID:31892268). JAK1 function is non-redundant in vivo: conditional deletion impairs hematopoietic stem cell self-renewal, cytokine sensing, and NK cell development, and JAK2 cannot compensate for its loss (PMID:28965767, PMID:30671064). Beyond canonical STAT signaling, JAK1 directly phosphorylates a defined set of substrates: PERK during ER stress to drive a PERK/JAK1/STAT3 axis (PMID:25113558), SIRT1 at Y280/Y301 to enable SIRT1-STAT3 negative feedback (PMID:29789426), and PD-L1 at Y112 to recruit STT3A and stabilize PD-L1 glycosylation, linking IL-6/JAK1 signaling to immune evasion (PMID:31305264). JAK1 activity is tightly controlled by multiple layers: dephosphorylation by receptor-associated PTPs including TCPTP (PMID:9238016, PMID:18948751), proteasomal turnover modulated by SOCS1 competition (antagonized by EHBP1L1) (PMID:36775874), HDAC1-dependent acetylation at K1109 (PMID:39384195), and positive regulation by ZDHHC3/7-mediated palmitoylation that facilitates activation-loop transphosphorylation (PMID:37356718). Its catalytic state is further shaped by activating hinge mutations that confer drug resistance (PMID:21393331) and by a JAK1-selective allosteric cysteine (C817) in the pseudokinase domain that is targetable by electrophilic inhibitors (PMID:36097295). Loss-of-function JAK1 mutations abrogate IFN-γ responsiveness and PD-L1 induction, mediating resistance to PD-1 blockade (PMID:27903500), while biallelic missense mutations cause a human immune dysregulation phenotype with impaired cytokine signaling (PMID:28008925).

Mechanistic history

Synthesis pass · year-by-year structured walk · 34 steps
  1. 1993 High

    Established that JAK1 is an essential, non-redundant component of interferon signaling, defining its core role as a receptor-coupled kinase required for STAT pathway activation.

    Evidence Genetic complementation of a JAK1-deficient cell line with loss-of-function and rescue across IFN-α/β and IFN-γ responses

    PMID:8232552

    Open questions at the time
    • Did not resolve the molecular basis of receptor complex assembly
    • Did not establish substrate specificity beyond STATs
  2. 1997 Medium

    Defined the kinase hierarchy and constitutive negative regulation of JAK1, showing its kinase activity acts upstream of TYK2 and that receptor-associated PTPs suppress persistent JAK1 activity.

    Evidence Dominant-negative kinase-dead mutants for pathway ordering; pervanadate PTP inhibition with JAK1-deficient cell complementation

    PMID:9238016 PMID:9249040

    Open questions at the time
    • Identity of the responsible receptor-associated phosphatase not pinned down here
    • Mechanism of dimerization-independent activation not defined
  3. 1997 Medium

    Extended JAK1 function beyond cytokine signaling to embryonic development, indicating a role in morphogenetic movements and patterning.

    Evidence Dominant-negative Jak1 RNA injection in zebrafish with epiboly and goosecoid phenotype readouts

    PMID:9096349

    Open questions at the time
    • Dominant-negative may not phenocopy null
    • Receptor/ligand upstream of developmental JAK1 not identified
  4. 1998 Medium

    Showed viral proteins can hijack JAK1 selectively, with HBx directly binding and activating JAK1 to drive STAT3/STAT5.

    Evidence Co-IP, in vitro kinase assay, and STAT DNA-binding assays in HBx-expressing cells

    PMID:9738022

    Open questions at the time
    • Binding interface on JAK1 not mapped
    • Single-lab; physiological relevance to HBV pathogenesis not established here
  5. 2003 High

    Demonstrated a tumor-suppressive function for JAK1 via IFN-γ-dependent growth arrest, linking JAK1 loss to increased tumorigenicity.

    Evidence Jak1-deficient v-abl-transformed pre-B cells with in vivo transplantation and IFN-γ response assays

    PMID:12576323

    Open questions at the time
    • Did not address JAK1 oncogenic gain-of-function contexts
    • Downstream effectors of growth arrest not fully defined
  6. 2007 High

    Positioned JAK1 as a proliferation checkpoint in muscle, acting through a LIF/JAK1-STAT1-STAT3 axis to repress premature differentiation.

    Evidence siRNA knockdown in primary and immortalized myoblasts with differentiation marker and proliferation readouts

    PMID:17908914

    Open questions at the time
    • Direct STAT targets controlling differentiation genes not mapped
    • Receptor mediating LIF input not specified
  7. 2008 Medium

    Identified TCPTP as a specific phosphatase dephosphorylating JAK1 during the cell cycle, refining the negative regulatory machinery.

    Evidence TCPTP-knockout MEFs and HeLa RNAi with cell cycle analysis

    PMID:18948751

    Open questions at the time
    • JAK1/STAT3 signaling dispensable for the observed G1/S phenotype, decoupling phosphatase target from function
    • Direct dephosphorylation site on JAK1 not defined
  8. 2008 Medium

    Provided chemical-biology evidence that small molecules can directly engage and inhibit JAK1, with myricetin binding JAK1 to block its phosphorylation.

    Evidence Pull-down/affinity binding assays and phospho-JAK1 western blots with transformation assay

    PMID:18995957

    Open questions at the time
    • Binding site not localized
    • Selectivity over other JAKs not established
  9. 2011 Medium

    Showed JAK1 can be oncogenically activated by kinase-domain hinge mutations (F958/P960) that also confer ATP-competitive inhibitor resistance.

    Evidence Spontaneous transformation screen in BaF3 cells with mutation sequencing and inhibitor sensitivity assays

    PMID:21393331

    Open questions at the time
    • Structural basis of constitutive activation not solved here
    • Clinical prevalence not addressed
  10. 2011 Medium

    Revealed receptor-level negative regulation through binding-site competition, with TRAF6 occluding the JAK1-binding site on IL-2Rβ.

    Evidence Traf6-knockout T cells/MEFs with IL-2R β-chain binding-site mutagenesis and JAK1/Erk readouts

    PMID:21155952

    Open questions at the time
    • Generality across other cytokine receptors not tested
    • Single-lab
  11. 2014 Medium

    Identified a non-canonical activation route in which ER stress activates JAK1 PERK-dependently and JAK1 phosphorylates PERK, defining a PERK/JAK1/STAT3 inflammatory axis.

    Evidence ER stress induction with PERK disruption and JAK1 inhibition in astrocytes

    PMID:25113558

    Open questions at the time
    • Direct PERK phosphosites by JAK1 not mapped
    • Whether interaction is direct not fully established
  12. 2015 Medium

    Connected chemokine signaling to cytoskeletal reorganization, showing CXCL12/CXCR4 engages JAK1/JAK2 to support immune synapse formation.

    Evidence Pharmacological JAK inhibition and CXCR4 downregulation with actin/MTOC and T cell activation readouts

    PMID:25917087

    Open questions at the time
    • JAK1-specific contribution vs JAK2 not separated
    • Direct substrates in synapse formation unknown
  13. 2016 Medium

    Defined a scaffold-based off-switch in which AJUBA binds the JAK1 FERM domain to dissociate JAK1 from the IFN-γ receptor and suppress STAT1 signaling.

    Evidence Co-IP with domain mapping, STAT1 phosphorylation, IFIT2 readouts, and xenografts

    PMID:27893714

    Open questions at the time
    • Stoichiometry of dissociation not quantified
    • Single-lab
  14. 2016 High

    Established the clinical consequence of JAK1 loss-of-function, showing tumor JAK1 mutations abolish IFN-γ-induced PD-L1 and ISG induction to drive PD-1 blockade resistance.

    Evidence Tumor biopsy sequencing with melanoma cell line IFN-γ stimulation and PD-L1 readouts

    PMID:27903500

    Open questions at the time
    • Did not enumerate full ISG dependency
    • Did not address gain-of-function tumor contexts
  15. 2016 High

    Linked biallelic JAK1 missense mutations to a human immune dysregulation phenotype and uncovered a phosphorylation-independent JAK1 function in signal transduction.

    Evidence Patient-derived cells, exome sequencing, and reconstitution in JAK1-deficient cells

    PMID:28008925

    Open questions at the time
    • Molecular basis of the phosphorylation-independent role not defined
    • Genotype-phenotype across additional families limited
  16. 2018 High

    Identified SIRT1 as a direct JAK1 substrate (Y280/Y301), revealing a feedback loop where JAK1 phosphorylation licenses SIRT1 to suppress STAT3 acetylation.

    Evidence In vitro kinase assay, site-directed mutagenesis, and STAT3 acetylation/transcription assays after IL-6

    PMID:29789426

    Open questions at the time
    • Structural consequence of Y280/Y301 phosphorylation not resolved
    • Single-lab
  17. 2019 High

    Defined a non-redundant role for JAK1 in NK cell development and tumor surveillance that JAK2 cannot substitute for.

    Evidence NK-specific conditional Jak1 knockout (Ncr1Cre) with developmental, functional, and tumor surveillance readouts versus JAK2 KO

    PMID:30671064

    Open questions at the time
    • Cytokine receptor input(s) driving NK dependence not isolated
    • Downstream STAT specificity in NK cells not resolved
  18. 2019 High

    Showed JAK1 directly phosphorylates PD-L1 at Y112 to recruit STT3A for glycosylation-dependent stabilization, mechanistically coupling IL-6/JAK1 to immune evasion.

    Evidence In vitro kinase assay, phospho-specific antibody, PD-L1 Y112 mutagenesis, glycosylation assay, and animal models

    PMID:31305264

    Open questions at the time
    • Whether JAK1-PD-L1 phosphorylation occurs at receptor or ER not localized
    • Generality across cancer types not fully mapped
  19. 2019 Medium

    Demonstrated JAK1-specific (not JAK2) STAT3 activation by extrinsic IL-6 in TKI-treated CML stem cells, nominating JAK1 as a co-target for leukemic stem cell eradication.

    Evidence Selective JAK1/2 inhibitors, genetic JAK1 inactivation, IL-6 blocking, CFU assay, and transgenic CML model

    PMID:30842608

    Open questions at the time
    • Direct vs indirect JAK1-STAT3 coupling not dissected
    • Single-lab
  20. 2019 High

    Established JAK1 as essential for hematopoietic stem cell self-renewal, stress response, and cytokine sensing, with constitutively active JAK2 unable to rescue JAK1 loss.

    Evidence Conditional Jak1 knockout mice with transplantation, cell cycle, cytokine stimulation, and competitive repopulation assays

    PMID:28965767

    Open questions at the time
    • Specific receptors mediating HSC dependence not isolated
    • Mechanism of JAK2 non-redundancy not defined
  21. 2019 Medium

    Showed an orphan TNF receptor (TROY) can directly engage and activate JAK1 to drive STAT3-dependent glioma malignancy, broadening the receptor partners of JAK1.

    Evidence Co-IP, JAK1 siRNA/ruxolitinib, STAT3 reporter, and migration assays

    PMID:32629176

    Open questions at the time
    • Binding region on JAK1 not mapped
    • Single-lab
  22. 2019 Medium

    Dissected the receptor-context-dependent regulatory role of the JAK1 pseudokinase (JH2) domain, showing JH2 (rather than kinase activity) is the key requirement in IFN-γ signaling and that JAK1 is dominant in IL-2 signaling.

    Evidence JAK-deficient cell lines with structure-based JH2 mutagenesis (L633) and STAT phosphorylation assays across cytokine systems

    PMID:31892268

    Open questions at the time
    • Structural mechanism of JH2 regulation not solved
    • Single-lab
  23. 2022 High

    Identified a JAK1-selective allosteric cysteine (C817) in the pseudokinase domain as a functional, druggable site for isoform-selective inhibition.

    Evidence Chemical proteomics, covalent labeling, and C817A mutagenesis with STAT phosphorylation and cytokine signaling assays

    PMID:36097295

    Open questions at the time
    • How C817 engagement allosterically blocks trans-phosphorylation not structurally resolved
  24. 2022 High

    Showed an endogenous metabolite (itaconate) directly modifies multiple JAK1 cysteines to inhibit its kinase activity, coupling immunometabolism to JAK1 control.

    Evidence Mass spectrometry of cysteine adducts (C715/C816/C943/C1130), in vitro kinase assay, and macrophage polarization assays in vitro/in vivo

    PMID:35235776

    Open questions at the time
    • Relative contribution of individual cysteines to inhibition not ranked
    • Endogenous itaconate concentrations achieving inhibition not benchmarked
  25. 2022 Medium

    Added a developmental/cancer JAK1 partner with DPYSL2 directly binding JAK1 to enable STAT3-driven migration and metastasis.

    Evidence Co-IP, DPYSL2 knockout, migration/invasion assays, and xenograft

    PMID:35575798

    Open questions at the time
    • Whether binding alters JAK1 catalytic activity unclear
    • Single-lab
  26. 2022 Medium

    Revealed a noncanonical JAK1/STAT3 axis controlling TGF-β signaling, with JAK1 binding TβRI and unphosphorylated STAT3 modulating SMAD3 and ECM production in fibroblasts.

    Evidence Co-IP, siRNA, upadacitinib, SMAD3 phosphorylation, and in vivo fibrosis model

    PMID:36283961

    Open questions at the time
    • Direction of JAK1 effect (suppressive) mechanistically unusual and not fully resolved
    • Single-lab
  27. 2022 High

    Defined a viral immune-evasion strategy where influenza PB2 ubiquitinates JAK1 at K859/K860 for degradation, blunting type I IFN signaling.

    Evidence Co-IP, ubiquitination assay, K859/K860 mutagenesis, and STAT/viral replication readouts across IAV subtypes

    PMID:36271046

    Open questions at the time
    • Host E3 ligase recruited by PB2 not identified
    • Whether these lysines are used by endogenous turnover unclear
  28. 2023 High

    Established palmitoylation as a positive regulatory modification, with ZDHHC3/7 palmitoylating JAK1 to enable activation-loop transphosphorylation and kinase activity.

    Evidence Palmitoylation assays, ZDHHC screening/knockdown, in vitro kinase assay, and neuronal survival/cytokine signaling readouts

    PMID:37356718

    Open questions at the time
    • Palmitoylated residue(s) not pinpointed in this summary
    • How leukemic mutation overrides palmitoylation-dependence not detailed
  29. 2023 High

    Identified acetylation as a degradative control point, with HDAC1 deacetylating JAK1 at K1109 to stabilize it and sustain STAT3-driven FGL1 transcription.

    Evidence Mass spectrometry, site mutagenesis, proteasome inhibition, ChIP, and in vivo tumor model

    PMID:39384195

    Open questions at the time
    • Acetyltransferase opposing HDAC1 not identified
    • Single-lab
  30. 2023 Medium

    Defined SOCS1-antagonizing stabilization, with EHBP1L1 competing with SOCS1 for JAK1 to protect it from degradation and maintain JAK1/STAT1/PD-L1 signaling.

    Evidence Co-IP competition, protein stability and proteasome rescue assays, and PDX models

    PMID:36775874

    Open questions at the time
    • Binding interface overlap with SOCS1 not structurally mapped
    • Single-lab
  31. 2023 Medium

    Added an epitranscriptomic layer, with METTL3-deposited m6A on JAK1 mRNA promoting JAK1 translation via YTHDF1 to amplify STAT3 signaling.

    Evidence m6A-seq, YTHDF1 co-IP, ribosome profiling, and METTL3 catalytic mutant in colorectal cancer

    PMID:38001065

    Open questions at the time
    • Specific m6A sites in 3'UTR not functionally validated individually
    • Single-lab
  32. 2023 Medium

    Showed JAK1 kinase activity is co-opted within the HDV replication complex, modulating ERK1/2 and S-HDAg phosphorylation required for replication.

    Evidence siRNA/JAK1 inhibitors, co-IP, and HDV replication assays in primary hepatocytes

    PMID:37925078

    Open questions at the time
    • Whether JAK1 phosphorylates S-HDAg directly not established
    • Single-lab
  33. 2024 Medium

    Uncovered a DNA damage-driven, receptor-independent activation mode where JAK1-SQ phosphorylation relieves JH2 autoinhibition to drive STAT6/GAS6/TAM signaling and chemoresistance.

    Evidence Phospho-profiling, filgotinib inhibition, STAT6 translocation, GAS6 secretion, and chemosensitization in Ewing sarcoma

    PMID:38906855

    Open questions at the time
    • Kinase responsible for JAK1-SQ phosphorylation not identified
    • Single-lab
  34. 2025 Medium

    Positioned STING as a direct JAK1 partner downstream of IFNAR, with palmitoylated STING (C91) promoting JAK1 phosphorylation to drive tumor vessel normalization.

    Evidence Co-IP, STING C91 palmitoylation-site mutagenesis, endothelial STING deletion, and in vivo tumor models

    PMID:39817453

    Open questions at the time
    • How STING palmitoylation enables JAK1 engagement structurally unclear
    • Single-lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the full network of post-translational modifications (palmitoylation, acetylation, ubiquitination, cysteine modification) and pseudokinase-domain control are integrated to set JAK1 activity in distinct receptor and cellular contexts remains unresolved.
  • No unified structural model linking JH2 regulation to receptor context
  • Cross-talk and hierarchy among competing JAK1 PTMs not established
  • Substrate selection rules beyond STATs not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 4 GO:0140096 catalytic activity, acting on a protein 4 GO:0098772 molecular function regulator activity 3 GO:0140657 ATP-dependent activity 2
Localization
GO:0005886 plasma membrane 3 GO:0005829 cytosol 2
Pathway
R-HSA-168256 Immune System 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
AJUBAJAK2PERKSIRT1STAT3STINGTCPTPTYK2
Complex memberships
cytokine receptor-JAK signaling complex

Evidence

Reading pass · 35 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1993 JAK1 is required for both interferon-alpha/beta and interferon-gamma signal transduction. A JAK1-deficient cell line was completely defective in interferon response; complementation with JAK1 restored signaling. JAK1 and TYK2 are mutually dependent in the IFN-α pathway, and JAK1 and JAK2 are mutually dependent in the IFN-γ pathway, likely reflecting a requirement for these kinases in correct assembly of interferon receptor complexes. Genetic complementation of JAK1-deficient mutant cell line; loss-of-function + rescue Nature High 8232552
1997 Receptor-associated constitutive protein tyrosine phosphatase (PTP) activity controls JAK1 kinase function. Inhibition of PTP activity with pervanadate activates JAKs and leads to JAK1-dependent, IL-4Rα-mediated STAT6 activation independently of receptor dimerization. This indicates that constitutive PTP activity suppresses persistent receptor-linked JAK1 activity. Pharmacological PTP inhibition (pervanadate), JAK1-deficient cell lines, complementation with IL-4Rα; loss-of-function and rescue Proceedings of the National Academy of Sciences of the United States of America High 9238016
1997 Kinase-deficient dominant-negative forms of JAK1 and TYK2 each independently inhibit IFN-α–induced STAT phosphorylation and transcriptional activation, establishing that JAK1 kinase activity is required upstream of TYK2 in the IFN-α signaling cascade. Transfection of kinase-deficient mutants; dominant-negative assay; reporter gene assay; STAT phosphorylation analysis European journal of biochemistry Medium 9249040
1997 Jak1 kinase is required for a specific cell migration (epiboly) and anterior specification in zebrafish embryos. Injection of dominant-negative Jak1 RNA reduces epiboly and decreases goosecoid expression and anterior structures, establishing a developmental role for JAK1 beyond cytokine signaling. Injection of dominant-negative Jak1 RNA into zebrafish embryos; developmental phenotype analysis Proceedings of the National Academy of Sciences of the United States of America Medium 9096349
1998 Hepatitis B virus HBx protein specifically activates JAK1 (but not JAK2 or TYK2) through direct protein–protein interaction with JAK1, elevating JAK1 tyrosine phosphorylation and kinase activity, and subsequently activating STAT3 and STAT5. Stable HBx-expressing cell lines; in vitro kinase assay; co-immunoprecipitation; STAT DNA-binding and transcriptional activation assays The Journal of biological chemistry Medium 9738022
2003 JAK1 is required for IFN-γ–mediated growth arrest and/or apoptosis of v-abl–transformed pre-B cells. JAK1-deficient transformed cells were more tumorigenic in vivo, and their increased tumorigenicity correlated with loss of IFN-γ responsiveness, establishing JAK1's role in intrinsic IFN-γ–dependent tumor surveillance rather than in promotion of tumorigenesis. Jak1-deficient mouse model; v-abl transformation; in vivo transplantation (SCID/nude mice); IFN-γ response assays Blood High 12576323
2007 JAK1 is required for myoblast proliferation and acts as a checkpoint preventing premature differentiation. JAK1 knockdown induces accelerated MyoD, MEF2, p21Cip1, and p27Kip1 induction and faster Id1 downregulation. Downstream, JAK1-STAT1-STAT3 constitutes the pathway through which LIF stimulates myoblast proliferation and represses differentiation. JAK1 knockdown (siRNA) in primary and immortalized myoblasts; gene expression analysis; cell proliferation assays The Journal of cell biology High 17908914
2008 Myricetin directly binds to JAK1 (and STAT3) with higher affinity for JAK1 than STAT3, inhibiting JAK1 phosphorylation and EGF-induced cell transformation. Ex vivo and in vitro pull-down assays confirmed direct binding; myricetin inhibited JAK1 phosphorylation without affecting EGFR autophosphorylation. Pull-down assay (ex vivo and in vitro); affinity binding assay; western blot for JAK1 phosphorylation; colony transformation assay Cancer letters Medium 18995957
2008 TCPTP (protein tyrosine phosphatase) dephosphorylates and negatively regulates JAK1 and STAT3 signaling during the cell cycle. TCPTP-deficient MEFs show enhanced SFK, JAK1, and STAT3 activation; however, JAK1 and STAT3 (not SFK) signaling was not required for the enhanced G1/S transition observed. TCPTP knockout MEFs; RNA interference in HeLa cells; pharmacological inhibitors; cell cycle analysis Cell cycle (Georgetown, Tex.) Medium 18948751
2011 Activating mutations in JAK1 at Phe958 and Pro960 (hinge region of kinase domain) render JAK1 constitutively active and resistant to ATP-competitive JAK inhibitors. These mutations can both activate JAK1 oncogenically and confer drug resistance. Spontaneous cellular transformation screen in BaF3 cells; sequencing of JAK1 mutations; inhibitor sensitivity assays Haematologica Medium 21393331
2014 ER stress activates JAK1 in astrocytes in a PERK-dependent manner. JAK1 phosphorylates PERK, and this PERK/JAK1/STAT3 axis drives IL-6 and chemokine expression. Disruption of PERK abrogates ER stress–induced STAT3 activation. Pharmacological ER stress induction; PERK disruption; JAK1 inhibition; western blot for STAT3 activation; gene expression analysis Molecular and cellular biology Medium 25113558
2015 CXCL12/CXCR4 signaling promotes immunological synapse formation and T cell activation through Gi and JAK1/JAK2 kinase activation, contributing to actin polymerization at the APC contact site and MTOC polarization. CXCR4 blockade/downregulation; pharmacological JAK inhibition; actin polymerization assay; MTOC polarization analysis; T cell activation markers Journal of immunology Medium 25917087
2016 Loss-of-function JAK1 mutations in tumor cells result in inability to respond to interferon-gamma (IFN-γ), preventing IFN-γ–induced PD-L1 expression and interferon-stimulated gene induction, thereby mediating primary resistance to PD-1 blockade. Tumor biopsy sequencing; melanoma cell line functional assays; IFN-γ stimulation with PD-L1 expression readout; JAK1/2 mutation characterization Cancer discovery High 27903500
2016 Biallelic JAK1 missense mutations (P733L and P832S) cause reduced JAK1 and STAT phosphorylation following cytokine stimulation, reduced interferon-regulated gene induction, and dysregulated cytokine production. The P733L mutation is primarily responsible. Reconstitution experiments revealed a phosphorylation-independent role of JAK1 in signal transduction. Patient-derived cells; exome sequencing; cytokine stimulation assays; STAT phosphorylation; reconstitution experiments in JAK1-deficient cells Nature communications High 28008925
2016 AJUBA LIM protein binds specifically to the FERM domain of JAK1 to dissociate JAK1 from the IFN-γ receptor, inhibiting STAT1 phosphorylation and nuclear translocation, thereby suppressing the JAK1-STAT1-IFIT2 network and promoting cancer cell survival. Co-immunoprecipitation; domain mapping; STAT1 phosphorylation assay; IFIT2 expression analysis; cell viability and xenograft assays Oncogene Medium 27893714
2017 Conditional Jak1 deletion in hematopoietic stem cells (HSCs) reduces self-renewal, alters lymphoid/myeloid differentiation, decreases competitiveness, prevents cell cycle entry in response to hematopoietic stress, and markedly reduces cytokine sensing including to type I interferons and IL-3. JAK2 constitutive activation cannot fully rescue JAK1 loss in HSCs. Conditional Jak1 knockout mouse model; in vivo transplantation; cell cycle analysis; cytokine stimulation assays; competitive repopulation assay Cell stem cell High 28965767
2018 JAK1 phosphorylates SIRT1 at tyrosine residues Y280 and Y301 within the histone deacetylase catalytic domain in response to IL-6 stimulation. This phosphorylation does not alter SIRT1 deacetylase activity but is required for SIRT1 interaction with STAT3, enhancing SIRT1 suppression of STAT3 acetylation and transcriptional activity, constituting a negative feedback of the JAK1-STAT3 pathway. Co-immunoprecipitation; in vitro kinase assay; site-directed mutagenesis (Y280A, Y301A); STAT3 acetylation assay; transcriptional activity assay The Journal of biological chemistry High 29789426
2019 IL-6-activated JAK1 directly phosphorylates PD-L1 at Tyr112, which recruits the ER-associated N-glycosyltransferase STT3A to catalyze PD-L1 glycosylation and maintain PD-L1 stability, linking oncogenic IL-6/JAK1 signaling to immune evasion. In vitro kinase assay; phospho-specific antibody; co-immunoprecipitation; glycosylation assay; mutagenesis of PD-L1 Y112; animal models The Journal of clinical investigation High 31305264
2019 JAK1 (not JAK2) is the STAT3-activating kinase mediating extrinsically activated STAT3 in TKI-treated CML stem cells, driven by IL-6. This was established using selective JAK1/2 inhibitors and genetic inactivation, and combined Bcr-Abl + JAK1 inhibition reduced CML stem cell colony formation and leukemic stem cells. Selective JAK1/2 inhibitors; genetic JAK1 inactivation; IL-6 blocking peptide; CFU assay; transgenic CML mouse model Leukemia Medium 30842608
2019 Conditional deletion of JAK1 (but not JAK2) in NKp46+ NK cells markedly reduces NK cell numbers in bone marrow, spleen, blood, and liver, impairs NK cell development, and impairs NK cell–mediated tumor surveillance. JAK2 is dispensable for NK cell survival and cannot compensate for JAK1 loss. Conditional NK cell–specific Jak1 knockout (Jak1Ncr1Cre); NK cell number/function assessment; tumor surveillance assay; comparison with JAK2-conditional KO Frontiers in immunology High 30671064
2019 TROY (orphan TNF receptor) directly interacts with JAK1, increases JAK1 phosphorylation, and promotes STAT3 phosphorylation and transcriptional activity in a JAK1-dependent manner. JAK1 inhibition or knockdown significantly inhibits TROY-induced STAT3 activation, GBM cell migration, and temozolomide resistance. Co-immunoprecipitation; JAK1 phosphorylation assay; STAT3 reporter assay; JAK1 siRNA knockdown; ruxolitinib pharmacological inhibition; migration assay Neoplasia (New York, N.Y.) Medium 32629176
2019 The JAK1 pseudokinase domain (JH2) has distinct regulatory functions across different receptor complexes: in IL-2 signaling JAK1 is dominant over JAK3 and strictly requires both JH1 and JH2; in IFN-γ signaling both JAK1 and JAK2 are indispensable for STAT1 activation and JAK1 JH2 (rather than kinase activity) is the key requirement. Mutations in the JAK1 JH2 αC-helix (L633) reduce basal and cytokine-induced STAT activation. JAK-deficient cell lines; structure-based mutagenesis; cytokine stimulation assays; STAT phosphorylation analysis Cancers Medium 31892268
2019 TRAF6 negatively regulates JAK1 activation in IL-2 signaling by binding to the TRAF6-binding site on the IL-2R β-chain, which overlaps with the JAK1-binding site. A β-chain mutation that inactivates TRAF6 binding while retaining JAK1 binding abrogated TRAF6-dependent reduction in JAK1-Erk pathway activation. Traf6-knockout T cells and MEFs; IL-2 signaling reconstitution; β-chain binding-site mutagenesis; JAK1 phosphorylation and Erk activation assays Genes to cells Medium 21155952
2022 Itaconate and 4-octyl itaconate (OI) directly modify JAK1 at multiple cysteine residues (C715, C816, C943, C1130) and inhibit JAK1 kinase activity and phosphorylation, suppressing M2 macrophage polarization in response to IL-4, IL-13, IFN-β, and IFN-γ in vitro and in vivo. Direct chemical modification identified by mass spectrometry; in vitro kinase activity assay; JAK1 phosphorylation analysis; M2 polarization assays in macrophages and Th2 cells; in vivo OI treatment Cell metabolism High 35235776
2022 JAK1 contains a druggable allosteric cysteine (C817) in its non-catalytic pseudokinase domain (absent from JAK2 and JAK3). Electrophilic compounds targeting C817 block JAK1-dependent trans-phosphorylation and cytokine signaling. Cells expressing a C817A JAK1 mutant are insensitive to these allosteric inhibitors, confirming C817 as the functional engagement site. Chemical proteomics; electrophilic compound library; covalent labeling; C817A mutagenesis; STAT phosphorylation assays; cytokine signaling assays Nature chemical biology High 36097295
2022 Influenza A virus PB2 protein targets mammalian JAK1 at lysine residues K859 and K860 for ubiquitination and proteasomal degradation, suppressing IFN-α/β signaling and STAT1/STAT2 activation as a mechanism of immune evasion. Co-immunoprecipitation; ubiquitination assay; site-specific mutagenesis (K859/K860); JAK1 protein level analysis; STAT phosphorylation assay; viral replication assay Nature communications High 36271046
2022 DPYSL2 (dihydropyrimidinase-like 2) directly interacts with JAK1, and this binding is required for activating STAT3 and subsequent vimentin expression, promoting breast cancer cell migration and metastasis. Co-immunoprecipitation; DPYSL2 knockout; migration/invasion assays; STAT3 phosphorylation analysis; in vivo xenograft The Journal of cell biology Medium 35575798
2022 JAK1 directly interacts with TGF-β receptor I subunit (TβRI). Silencing JAK1 promotes myofibroblast transdifferentiation; this is mediated via constitutive STAT3 activation that requires JAK1. Silencing unphosphorylated STAT3 suppresses TGF-β signaling, SMAD3 activation, and ECM production, revealing a noncanonical JAK1/STAT3 regulatory axis in lung fibroblasts. Co-immunoprecipitation; siRNA silencing; upadacitinib pharmacological inhibition; SMAD3 phosphorylation assay; myofibroblast differentiation assay; in vivo fibrosis model American journal of physiology. Lung cellular and molecular physiology Medium 36283961
2023 HDAC1 deacetylates JAK1 at lysine 1109; HDAC inhibition (SAHA) increases JAK1 K1109 acetylation, promoting JAK1 proteasomal degradation and reducing STAT3-driven FGL1 transcription, thereby enhancing CD8+ T cell antitumor activity. Co-immunoprecipitation; mass spectrometry; site-specific mutagenesis; proteasome inhibitor assay; STAT3 activity assay; chromatin immunoprecipitation; in vivo tumor model Journal for immunotherapy of cancer High 39384195
2023 EHBP1L1 interacts with and stabilizes JAK1 protein by competing with SOCS1 for JAK1 binding, thereby protecting JAK1 from proteasomal degradation and maintaining elevated JAK1/STAT1/PD-L1 signaling in renal cell carcinoma. Co-immunoprecipitation; EHBP1L1 depletion; protein stability assay; proteasome inhibitor rescue; STAT1/PD-L1 expression analysis; PDX tumor model Advanced science Medium 36775874
2023 JAK1 is palmitoylated endogenously in dorsal root ganglion (DRG) neurons and in HEK293T cells. ZDHHC3 and ZDHHC7 are the dominant protein acyltransferases (PATs) for JAK1. Palmitoylation is critical for JAK1 kinase activity (even in vitro) and facilitates transphosphorylation of key activation loop sites, but minimally affects JAK1 localization in neurons. A leukemia-associated JAK1 mutation overrides palmitoylation-dependence of JAK1 activity. JAK1 palmitoylation is required for neuropoietic cytokine-dependent signaling and neuronal survival. Palmitoylation assay; ZDHHC screening; shRNA knockdown; in vitro kinase assay; neuronal survival assay; cytokine signaling assays; structural modeling The Journal of biological chemistry High 37356718
2023 METTL3 deposits m6A on the 3' UTR of JAK1 mRNA to promote JAK1 translation via YTHDF1 recognition, increasing JAK1 protein levels and contributing to STAT3 pathway activation and colorectal cancer progression. m6A-seq; YTHDF1 co-immunoprecipitation; ribosome profiling; JAK1 reporter assay; METTL3 catalytic mutant Cell death & disease Medium 38001065
2023 JAK1 kinase activity is required for HDV replication. JAK1 inhibition modulates ERK1/2 activation and S-HDAg (small hepatitis delta antigen) phosphorylation, which is crucial for viral replication. Co-immunoprecipitation confirmed JAK1 interaction within the HDV replication complex. Loss-of-function (siRNA/JAK1 inhibitors); co-immunoprecipitation; ERK1/2 and S-HDAg phosphorylation assays; HDV replication assay in primary human hepatocytes Journal of hepatology Medium 37925078
2024 Chemotherapy-induced JAK1 activation occurs through an alternative mechanism: DNA damage induces JAK1-SQ phosphorylation that releases JAK1 pseudokinase domain (JH2) inhibition, allowing JAK1 activation without cytokine receptor engagement. This leads to STAT6 nuclear translocation and GAS6 secretion, activating TAM kinases to confer chemoresistance in Ewing sarcoma. Phospho-profiling; JAK1 inhibition (filgotinib); STAT6 nuclear translocation assay; GAS6 secretion measurement; in vitro and in vivo chemosensitization assays Nature communications Medium 38906855
2025 STING acts downstream of IFN-α/β receptor (IFNAR) in endothelial cells and interacts directly with JAK1 upon IFN-I stimulation, promoting JAK1 phosphorylation. This interaction requires STING palmitoylation at Cysteine 91 but not the STING C-terminal tail (CTT) domain, and drives JAK1-STAT signaling for tumor vessel normalization and CD8+ T cell infiltration. Co-immunoprecipitation; STING palmitoylation-site mutagenesis (C91); IFN-I signaling assays; endothelial-specific STING deletion; JAK1 phosphorylation analysis; in vivo tumor models The Journal of clinical investigation Medium 39817453

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer discovery 1092 27903500
2010 Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England journal of medicine 982 20843246
1993 The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 729 8232552
2019 IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. The Journal of clinical investigation 308 31305264
2022 Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. Cell metabolism 269 35235776
2013 Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 204 23459451
1998 HBx protein of hepatitis B virus activates Jak1-STAT signaling. The Journal of biological chemistry 204 9738022
2014 PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. Molecular and cellular biology 200 25113558
2019 Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. The Journal of allergy and clinical immunology 181 31629805
2008 Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 170 18559588
2021 SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science immunology 163 33827897
2007 JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts. The Journal of cell biology 160 17908914
2006 PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways. Cell death and differentiation 108 16322752
2017 Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type. Molecular medicine reports 101 28901399
2020 Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. American journal of clinical dermatology 95 32776305
2016 Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nature communications 93 28008925
2018 Aloin suppresses lipopolysaccharide‑induced inflammation by inhibiting JAK1‑STAT1/3 activation and ROS production in RAW264.7 cells. International journal of molecular medicine 82 30066904
2017 Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice. Diabetes 76 28292965
2020 The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathology. Experimental & molecular medicine 73 32788655
2019 A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. Inflammatory bowel diseases 67 30668755
2022 Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine. Nature chemical biology 65 36097295
2022 The influenza virus PB2 protein evades antiviral innate immunity by inhibiting JAK1/STAT signalling. Nature communications 64 36271046
2011 Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 64 21393331
2016 The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network. Oncogene 61 27893714
2021 JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford, England) 60 33950226
2008 Myricetin directly targets JAK1 to inhibit cell transformation. Cancer letters 60 18995957
2020 The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes. Aging cell 58 32196928
2017 Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. Cell stem cell 58 28965767
1997 Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1. Proceedings of the National Academy of Sciences of the United States of America 57 9238016
2023 Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. EBioMedicine 54 37863021
2021 JAK1: Number one in the family; number one in inflammation? Rheumatology (Oxford, England) 54 33950229
2023 Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica 53 36861402
2019 Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs in context 52 31692920
2023 Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nature communications 49 37925520
2023 METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling pathway. Cell death & disease 49 38001065
2019 Loss of JAK1 Drives Innate Immune Deficiency. Frontiers in immunology 46 30671064
2018 The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 46 29939445
1997 Jak1 kinase is required for cell migrations and anterior specification in zebrafish embryos. Proceedings of the National Academy of Sciences of the United States of America 46 9096349
2019 The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clinical and experimental rheumatology 43 30767864
2019 Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia 43 30842608
2015 Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine & growth factor reviews 42 26188635
2014 Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood 39 25352124
2023 EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 36 36775874
2015 Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors. Journal of medicinal chemistry 36 26351728
2022 IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Cellular signalling 35 35820543
2012 Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert opinion on pharmacotherapy 34 23051187
2023 Selective JAK1 inhibitors for the treatment of inflammatory bowel disease. Pharmacology & therapeutics 32 37004800
2024 Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis. The Journal of experimental medicine 31 38563820
2024 HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma. Journal for immunotherapy of cancer 31 39384195
2012 Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert opinion on therapeutic patents 31 22971156
1997 Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner. European journal of biochemistry 31 9249040
2020 JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. The Journal of allergy and clinical immunology 29 33338537
2019 HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway. Cancer management and research 29 31406476
2015 CXCL12 Regulates through JAK1 and JAK2 Formation of Productive Immunological Synapses. Journal of immunology (Baltimore, Md. : 1950) 29 25917087
2003 Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood 29 12576323
2023 Successful treatment of JAK1-associated inflammatory disease. The Journal of allergy and clinical immunology 28 37343845
2020 FOXM1 activates JAK1/STAT3 pathway in human osteoarthritis cartilage cell inflammatory reaction. Experimental biology and medicine (Maywood, N.J.) 28 33297736
2019 Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling. Cancers 28 31892268
2023 Efficacy of JAK1/2 inhibition in murine immune bone marrow failure. Blood 27 36130301
2022 Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata. Frontiers in immunology 27 36203601
2022 Autoinflammatory Keratinization Disease With Hepatitis and Autism Reveals Roles for JAK1 Kinase Hyperactivity in Autoinflammation. Frontiers in immunology 26 35046931
2022 Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug design, development and therapy 26 36068788
2018 JAK1-mediated Sirt1 phosphorylation functions as a negative feedback of the JAK1-STAT3 pathway. The Journal of biological chemistry 26 29789426
1996 Expression, characterization, and genomic structure of carp JAK1 kinase gene. DNA and cell biology 26 8892755
2009 Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma 25 19239328
2020 SARS-CoV2 drives JAK1/2-dependent local and systemic complement hyper-activation. Research square 24 32702726
2015 Progress toward JAK1-selective inhibitors. Future medicinal chemistry 23 25686006
2013 Computational models of the JAK1/2-STAT1 signaling. JAK-STAT 23 24069559
2025 Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity. The Journal of clinical investigation 22 39817453
2022 Human JAK1 gain of function causes dysregulated myelopoeisis and severe allergic inflammation. JCI insight 22 36546480
2021 MicroRNA 452 regulates IL20RA-mediated JAK1/STAT3 pathway in inflammatory colitis and colorectal cancer. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 22 34283251
2008 Cell cycle-dependent regulation of SFK, JAK1 and STAT3 signalling by the protein tyrosine phosphatase TCPTP. Cell cycle (Georgetown, Tex.) 22 18948751
2019 Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance. Frontiers in immunology 21 30837996
2022 Curcumin attenuates intracerebral hemorrhage-induced neuronal apoptosis and neuroinflammation by suppressing JAK1/STAT1 pathway. Biochemistry and cell biology = Biochimie et biologie cellulaire 20 35381181
2022 Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis. American journal of physiology. Lung cellular and molecular physiology 19 36283961
2021 Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research 19 33782031
2020 TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance. Neoplasia (New York, N.Y.) 19 32629176
2024 Multispecies-targeting siRNAs for the modulation of JAK1 in the skin. Molecular therapy. Nucleic acids 18 38304729
2019 microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1. Cell cycle (Georgetown, Tex.) 18 30990343
2021 Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 17 33475190
2021 A novel activating JAK1 mutation in chronic eosinophilic leukemia. Blood advances 17 34496019
2021 Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer. Cancer letters 17 34627950
2010 TRAF6 negatively regulates the Jak1-Erk pathway in interleukin-2 signaling. Genes to cells : devoted to molecular & cellular mechanisms 17 21155952
2024 JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 16 38262152
2023 ANGPTL4 inhibits granulosa cell proliferation in polycystic ovary syndrome by EGFR/JAK1/STAT3-mediated induction of p21. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 16 36607250
2023 Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1/STAT3 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 16 37837898
2023 Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series. The Journal of dermatology 16 38115742
2018 Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo. Journal of pathology and translational medicine 16 30347972
2023 JAK1 promotes HDV replication and is a potential target for antiviral therapy. Journal of hepatology 15 37925078
2021 Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth. Journal of cellular and molecular medicine 15 33523587
2016 Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Bioorganic & medicinal chemistry letters 15 26927423
2016 Generation of Janus kinase 1 (JAK1) conditional knockout mice. Genesis (New York, N.Y. : 2000) 15 27671227
2024 Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. Nature communications 14 38906855
2024 Vitamin D3 attenuates autoimmune thyroiditis by regulating Th17/Treg cell differentiation via YAP/JAK1/STAT1 axis. Immunology letters 14 38959983
2023 Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease. International immunopharmacology 14 37988912
2022 DPYSL2 interacts with JAK1 to mediate breast cancer cell migration. The Journal of cell biology 14 35575798
2024 The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells. Frontiers in immunology 13 39188724
2023 Guanylate binding protein 5 accelerates gastric cancer progression via the JAK1-STAT1/GBP5/CXCL8 positive feedback loop. American journal of cancer research 13 37168340
2023 Palmitoylation-dependent control of JAK1 kinase signaling governs responses to neuropoietic cytokines and survival in DRG neurons. The Journal of biological chemistry 13 37356718
2016 Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Future oncology (London, England) 13 27785927

Missed literature

Know a paper Affinage missed for JAK1? Flag it for the maintainers and the community.

No submissions yet.